webinar series
Prevention and Management of Cancer Therapy-Related Cardiac Dysfunction: What's New?
Description
Cancer therapies such as anthracyclines, HER2-targeted agents and immune checkpoint inhibitors carry distinct cardiac risk profiles, and prevention starts before the first cycle. In this joint ISCP × IC-OS webinar, an international faculty of cardiologists and cardiovascular pharmacists reviewed the latest evidence on cardioprotective pharmacotherapy, discussed how to apply current guideline recommendations for risk stratification and CTRCD prevention, and worked through a real-world clinical case.
Moderator: Dr Joshua Bennetts (University of Newcastle, Australia). Faculty: Dr Colin Aspelund (UNC Eshelman School of Pharmacy, USA), Dr Suphat Subongkot (Khon Kaen University, Thailand), Dr Joe Carver (University of Pennsylvania, USA) and Dr Dan Lenihan (Saint Francis Healthcare System, USA).
The recording is now available on demand.
What Would You Learn
- Current evidence and updates on cardioprotective pharmacotherapies
- Guideline recommendations for risk stratification and CTRCD prevention
- Applying guidelines to specific populations
- Real-world integration of guidelines through a clinical case
About IC-OS
The International Cardio-Oncology Society (IC-OS) is a global professional society dedicated to protecting the cardiovascular health of patients undergoing cancer therapy. Through education, research and clinical collaboration, IC-OS brings together cardiologists, oncologists, haematologists, pharmacists and allied health professionals from more than 30 countries.
Learn more at ic-os.org
restricted content
ISCP Members Only
Access to the e-Learning and Experts sections is available to ISCP Members only. Already a Member? Log in Not yet a Member? Visit our Registration page for details of how to join the ISCP and learn more about the benefits of being a part.